Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po
Raziskovalni podatki


Iskalni niz: "ključne besede" (pandemics) .

1 - 3 / 3
Na začetekNa prejšnjo stran1Na naslednjo stranNa konec
The global impact of the COVID-19 pandemic on the management and course of chronic urticaria
Emek Kocatürk, Andaç Salman, Ivan Cherrez-Ojeda, Paulo Ricardo Criado, Jonny Peter, Elif Comert-Ozer, Mohamed Abuzakouk, Rosana Câmara Agondi, Mona Al-Ahmad, Sabine Altrichter, Mojca Bizjak, Mitja Košnik, 2020

Povzetek: Introduction: The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: To understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: Our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: The COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19. Conclusions: The COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation.
Ključne besede: chronic urticaria, pandemics, omalizumab, cyclosporine, COVID-19, SARS-CoV-2, UCARE, treatment
DiRROS - Objavljeno: 14.12.2020; Ogledov: 718; Prenosov: 169

Lower-limb muscle contractile properties, explosive power and the subjective response of elite soccer players to the Covid-19 lockdown
Armin Paravlić, Boštjan Šimunič, Saša Pišot, Matej Kleva, Kaja Teraž, Matjaž Vogrin, Uroš Marušič, Rado Pišot, 2022

Povzetek: The present study examined the effects of the lockdown period on basic anthropometric measures, countermovement jumping performance, skeletal muscle contractile properties derived from tensiomyography (TMG), injury incidence, and self-assessed general well-being in elite soccer players. A total of 266 players were assessed before (PRE) and 32 players were reassessed 11 days after (POST) the COVID-19 period. Significant changes in the TMG parameters were observed POST compared to PRE: contraction time (Tc) increased from 6% to 50% in vastus lateralis [VL] (p = 0.009) and biceps femoris [BF] (p < 0.001), respectively; whereas radial displacement (Dm) increased for 19% in BF (p = 0.036) and 17% in VL (p < 0.001), respectively. Jumping performance remained unchanged from PRE to POST In addition, athletes rated the lockdown period as a positive event and felt psychologically better during the lockdown, primarily because they spent more time with family members and friends. Although there were no differences in any of the variables describing lower limb muscle power following the two-month lockdown, the altered contractile properties of the assessed muscles suggest suboptimal conditioning of the football players.
Ključne besede: football, male football, power, explosive power, tensiomyography, coronavirus, covid-19, pandemics, lockdown
DiRROS - Objavljeno: 06.01.2022; Ogledov: 199; Prenosov: 150
.pdf Celotno besedilo (672,26 KB)

Mortality, seasonal variation, and susceptibility to acute exacerbation of COPD in the pandemic year : a nationwide population study
Irena Šarc, Aleša Lotrič Dolinar, Tina Morgan, Jože Sambt, Kristina Ziherl, Dalibor Gavrić, Julij Šelb, Aleš Rozman, Petra Došenović Bonča, 2022

Povzetek: Background: Previous studies have suggested that the coronavirus disease 2019 (COVID-19) pandemic was associated with a decreased rate of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Data on how the COVID-19 pandemic has influenced mortality, seasonality of, and susceptibility to AECOPD in the chronic obstructive pulmonary disease (COPD) population is scarce. Methods: We conducted a national population-based retrospective study using data from the Health Insurance Institute of Slovenia from 2015 to February 2021, with 2015–2019 as the reference. We extracted patient and healthcare data for AECOPD, dividing AECOPD into severe, resulting in hospitalisation, and moderate, requiring outpatient care. The national COPD population was generated based on dispensed prescriptions of inhalation therapies, and moderate AECOPD events were analysed based on dispensed AECOPD medications. We extracted data on all-cause and non-COVID mortality. Results: The numbers of severe and moderate AECOPD were reduced by 48% and 34%, respectively, in 2020. In the pandemic year, the seasonality of AECOPD was reversed, with a 1.5-fold higher number of severe AECOPD in summer compared to winter. The proportion of frequent exacerbators (2 AECOPD hospitalisations per year) was reduced by 9% in 2020, with a 30% reduction in repeated severe AECOPD in frequent exacerbators and a 34% reduction in persistent frequent exacerbators (2 AECOPD hospitalisations per year for 2 consecutive years) from 2019. The risk of two or more moderate AECOPD decreased by 43% in 2020. In the multivariate model, pandemic year follow-up was the only independent factor associated with a decreased risk for severe AECOPD (hazard ratio [HR]: 0.71; 95% confidence interval [CI]: 0.61–0.84; p < 0.0001). In 2020, non-COVID mortality decreased (−15%) and no excessive mortality was observed in the COPD population. Conclusion: In the pandemic year, we found decreased susceptibility to AECOPD across severity spectrum of COPD, reversed seasonal distribution of severe AECOPD and decreased non-COVID mortality in the COPD population.
Ključne besede: chronic obstructive pulmonary disease -- mortality, pandemics, seasons, exacerbation, acute exacerbation, seasonal variations, population study
DiRROS - Objavljeno: 14.03.2022; Ogledov: 85; Prenosov: 47

Iskanje izvedeno v 0 sek.
Na vrh